Ind-Swift Ltd.

NSE: INDSWFTLTD BSE: 524652 SECTOR: Pharmaceuticals & Drugs  2572   5   0

13.00
-0.65 (-4.76%)
NSE: 22 Oct 03:44 PM

Price Summary

Today's High

₹ 13.05

Today's Low

₹ 13

52 Week High

₹ 16.6

52 Week Low

₹ 2.4

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

70.41 Cr.

Enterprise Value

1070.45 Cr.

No. of Shares

5.42 Cr.

P/E

0

P/B

0

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  -137.82

CASH

16.76 Cr.

DEBT

1016.79 Cr.

Promoter Holding

55.55 %

EPS (TTM)

₹  -4.53

Sales Growth

14.01%

ROE

0 %

ROCE

5.82%

Profit Growth

-333.38 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.01%
3 Year7.8%
5 Year-4.61%

Profit Growth

1 Year-333.38%
3 Year24.88%
5 Year13.31%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year5.82%
3 Year-0.37%
5 Year-15.54%

Debt/Equity

-1.4258

Price to Cash Flow

2.04

Interest Cover Ratio

0.526515173044897

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 55.55 73.46
Jun 2021 55.55 73.46
Mar 2021 55.55 73.46
Dec 2020 55.55 73.46
Sep 2020 55.55 73.46
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -97.6615643167347 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 18.7305099453145.

 Limitations

  • The company has shown a poor revenue growth of 7.7982926041769% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Promoter pledging has increased from 55.55% to 73.46% in 1 quarter.
  • Company has a poor ROCE of -0.372243263300854% over the past 3 years
  • The company has a low EBITDA margin of -12.4697811171577% over the past 5 years.
  • The company has negative book value.
  • Promoter pledging is high as 73.46%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 61.31 95.98 104.76 94.01 90.42
Total Expenditure 51.6 81.35 87.23 94.51 79.77
Operating Profit 9.71 14.64 17.52 -0.49 10.65
Other Income 2.75 2.4 1.37 2.75 6.05
Interest 13.23 11.2 11.9 9.9 12.01
Depreciation 8.1 8.13 8.18 8.3 7.84
Exceptional Items 0 0 0 -1.21 0
Profit Before Tax -8.86 -2.29 -1.19 -17.15 -3.15
Tax 0 0 0 0.32 0.42
Profit After Tax -8.86 -2.29 -1.19 -17.47 -3.57
Adjusted EPS (Rs) -1.64 -0.42 -0.22 -3.23 -0.66

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 304.33 263.05 269.81 289.03 329.52
Total Expenditure 461.28 328.46 263.52 278.28 306.18
Operating Profit -156.95 -65.4 6.3 10.75 23.34
Other Income 12.51 13.68 14.57 8.44 22.38
Interest 18.97 16.32 11.46 3.77 35.19
Depreciation 36.35 35.73 34.63 33.97 33.59
Exceptional Items 0 -259.61 -28.15 26.74 6.4
Profit Before Tax -199.77 -363.37 -53.38 8.19 -16.66
Tax 0.17 0.89 0.75 0 2.46
Net Profit -199.94 -364.27 -54.13 8.19 -19.12
Adjusted EPS (Rs.) -39.71 -67.25 -9.99 1.51 -3.53

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 24.27 25.03 10.83 10.83 10.83
Total Reserves -263.75 -636.04 -690.2 -687.57 -723.95
Borrowings 671.65 664.77 681.2 644.67 644.21
Other N/C liabilities 7.68 7.45 12.7 14.62 16.42
Current liabilities 620.93 607.85 598.24 615.87 654.13
Total Liabilities 1060.78 669.06 612.77 598.42 601.65
Assets
Net Block 374.14 342.31 310.68 290.56 269.66
Capital WIP 2.22 2.22 0 0 0
Intangible WIP 1.45 0 0 0 0
Investments 45.12 43.9 43.91 41.26 24.06
Loans & Advances 16.31 74.19 72.06 73.09 79.27
Other N/C Assets 9.89 0 0 0 0
Current Assets 611.65 206.43 186.11 193.51 228.65
Total Assets 1060.78 669.06 612.77 598.42 601.65
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations -199.77 -363.37 -53.38 8.19 -19.12
Adjustment 168.51 321.15 73.12 21.32 52.68
Changes in Assets & Liabilities -74.54 48.95 -18.41 13.27 1.03
Tax Paid 0 0 0 0 0
Operating Cash Flow -105.79 6.72 1.34 42.79 34.6
Investing Cash Flow -4.01 -4.3 -2.73 -13.71 -11.35
Financing Cash Flow 110.21 -10.71 -4.04 -13.03 -26.2
Net Cash Flow 0.41 -8.28 -5.43 16.05 -2.96

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 55.55 55.55 55.55 55.55 55.55
essix biosciences ... 31.45 31.45 31.45 31.45 -
essix bioscienes l... - - - - 31.45
s.r. mehta 3.76 3.76 3.76 3.76 3.76
gopal munjal 3.61 3.61 3.61 3.61 3.61
v.r. mehta 3.55 3.55 3.55 3.55 3.55
sunita jain 3.35 3.35 3.35 3.35 3.35
neera mehta 2.86 2.86 2.86 2.86 2.86
ravi mehta 1.17 1.17 1.17 1.17 1.17
n.r. munjal 1.13 1.13 1.13 1.13 1.13
neeta munjal 1.07 1.07 1.07 1.07 1.07
nidhi munjal 0.93 0.93 0.93 0.93 0.93
himanshu jain 0.91 0.91 0.91 0.91 0.91
meenakshi mehta 0.74 0.74 0.74 0.74 0.74
annie mehta 0.29 0.29 0.29 0.29 0.29
rishav mehta 0.21 0.21 0.21 0.21 0.21
sahil munjal 0.21 0.21 0.21 0.21 0.21
saurabh munjal 0.10 0.10 0.10 0.10 0.10
ishav mehta 0.08 0.08 0.08 0.08 0.08
bhanavi mehta 0.06 0.06 0.06 0.06 0.06
deepti munjal 0.06 0.06 0.06 0.06 0.06
divya munjal 0.03 0.03 0.03 0.03 0.03
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 44.45 44.45 44.45 44.45 44.45
globe capital mark... - - - - -
panchkula finvest ... 1.31 1.31 1.31 1.31 1.31
altruistic trading... 2.04 1.96 1.65 1.54 -
united india insur... 1.76 1.76 - 1.76 -
deepa ram kheria 1.60 1.60 1.60 1.60 1.59
justin pharmaceuti... 1.59 1.59 1.59 1.59 1.59
sharwan singh gule... - - - - 1.48
rameshkumar javerc... 1.05 1.08 1.08 1.08 1.45
gravity systems pr... 1.38 1.38 1.38 1.38 1.38
excel motors priva... 1.08 1.08 1.08 1.08 1.08
iepf 0.91 0.91 0.91 0.91 0.91

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Ind-Swift Stock Price Analysis and Quick Research Report. Is Ind-Swift an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ind-Swift and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 34.5956 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ind-Swift has a Debt to Equity ratio of -1.4258 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ind-Swift , the EPS growth was -333.370793944602 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ind-Swift has OPM of 7.08178132933883 % which is a bad sign for profitability.
     
  • ROE: Ind-Swift have a poor ROE of 0 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Ind-Swift

X